Barcelona launches world’s first joint program on evolutionary medical genomics

Spyre Ther­a­peu­tics is pulling in $180 mil­lion in a pri­vate place­ment just a cou­ple of weeks af­ter it re­brand­ed from Ae­glea Bio­Ther­a­peu­tics. Spyre is sell­ing

Sanofi re­port­ed pos­i­tive Sar­clisa da­ta from a reg­is­tra­tional test in cer­tain new­ly-di­ag­nosed mul­ti­ple myelo­ma pa­tients, with the com­pa­ny an­tic­i­pat­ing a US launch as ear­ly as